As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…
HOME > BUSINESS
BUSINESS
- Takeda Inks US$3.7 Billion Loan Accord with JBIC
December 4, 2018
- Tokyo Prosecutors Take Novartis to Top Court
December 4, 2018
- Ninlaro Shows 39% Improvement in PFS in Post-Transplant Multiple Myeloma Patients: Takeda
December 4, 2018
- Astellas Launches Sakigake-Designated AML Drug Xospata
December 4, 2018
- Fujifilm Toyama Chemical Licenses Cancer “Theragnostic” Agent to Novartis Subsidiary
December 4, 2018
- MSD Japan Chief Voices High Hopes for Keytruda Label Expansions
December 3, 2018
- With Current R&D Model Reaching Its Limit, Industry Going Digital to Boost Efficiency: Astellas Chairman
December 3, 2018
- Lilly Launches Breast Cancer Drug Verzenio
December 3, 2018
- AbbVie Files Maviret for Pediatric Use for Age 12 and Older
December 3, 2018
- Olympus to Launch Japan Clinical Study of Regenerative Medicine Product for Traumatic Cartilage Defects
December 3, 2018
- ADHD Treatments to Reap 50% Growth in 2026, Despite Shrinking CNS Market: Fuji Keizai
December 3, 2018
- US FDA Approves Astellas’ AML Treatment Xospata
November 30, 2018
- Celgene Files Otezla for Additional Indication of Oral Ulcers due to Behcet’s Disease
November 30, 2018
- JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
November 30, 2018
- Kowa Reps Continue Heavy GP Detailing for Parmodia in August: Anterio
November 30, 2018
- Fycompa Hits Primary Endpoint in Monotherapy PIII, Eisai Eyes Filing by March-End
November 29, 2018
- Daiichi Sankyo, Roche to Collaborate on CDx Development for DS-8201
November 29, 2018
- JCR Launches Japan’s 1st Fabrazyme Biosimilar
November 29, 2018
- Daiichi Sankyo’s Herceptin Biosimilar Hits Shelves, Nippon Kayaku/Celltrion Earn Breast Cancer Nod
November 29, 2018
- Takeda’s Brigatinib Bags European OK for 2nd Line ALK-Positive NSCLC
November 29, 2018
ページ
Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…
To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…
While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…